论文部分内容阅读
目的研究肿瘤坏死因子和Ｎ－ＣＷＳ介入性治疗中晚期肝癌的临床与二步切除。方法２３２例中晚期肝癌随机分为免疫化疗栓塞组（治疗组）８０例，化疗栓塞组（对照组）１５２例，二组病期相似，均行肝动脉化疗栓塞，注入相向化疗方案和剂量（５－氟尿嘧啶、顺铂和阿霉素或丝裂霉素），用碘化油和明胶海棉为栓塞剂。治疗组同时配合肿瘤坏死因子和Ｎ－ＣＷＳ免疫治疗。结果治疗组１３例（１６．２％）、对照组１９例（１２．５％）行二步切除术，治疗组的肿瘤缩小率和二步切除率均比对照组高，治后１年、２年和３年生存率分别比对照组提高９．３％，８．６％和１１．０％（Ｐ＞０．０５）。免疫功能治疗组下降不明显（Ｐ＞０．０５），而对照组明显下降（Ｐ＜０．０５）。结论肿瘤坏死因子和Ｎ－ＣＷＳ介入性治疗能提高患者的免疫功能，延长生存期，具有广泛的应用前景。
Objective To investigate the clinical and two-step resection of advanced liver cancer with interventional therapy of tumor necrosis factor and N-CWS. Methods 232 cases of advanced hepatocellular carcinoma were randomly divided into immunochemotherapy embolization group (treatment group) 80 cases and chemotherapy embolization group (control group) 152 cases. The two groups were similar in duration and were all subjected to hepatic arterial chemoembolization, injecting the opposite chemotherapy regimen and dose ( 5-fluorouracil, cisplatin, and doxorubicin or mitomycin), using iodized oil and gelatin sponge as embolic agents. The treatment group also cooperated with tumor necrosis factor and N-CWS immunotherapy. Results Twenty-three patients (16.2%) in the treatment group and 19 patients (12.5%) in the control group underwent two-step resection. The tumor reduction rate and the two-step resection rate of the treatment group were higher than those of the control group. One year after treatment, The 2-year and 3-year survival rates were 9.3%, 8.6%, and 11.0%, respectively, higher than those of the control group (P>0.05). The immune function treatment group decreased significantly (P> 0.05), while the control group decreased significantly (P <0.05). Conclusion Interventional treatment of tumor necrosis factor and N-CWS can improve the patient’s immune function and prolong the survival period, which has broad application prospects.